May 03, 2004

When ‘Nano’ Isn’t Enough

FeRx, the San Diego producer of iron and activated carbon particles for drug delivery has discontinued its venture capital financing plans and may shut down. The main reason is a lack of clear results in a Phase II/III clinical trial utilizing the company's proprietary MagneTarg(TM) drug delivery system in patients with primary liver cancer (hepatocellular carcinoma or HCC).

As plenty of companies will find in the coming years, it takes more than a pinch of nanotechnology to get a drug to market, or even to keep investors interest long enough to get over the next hurdle.

One to scrub from the nanotech databases unless they can close that last $40 million series G?

Posted by Cientifica at May 3, 2004 05:20 PM | TrackBack
Post a comment

Remember personal info?